QSAR analysis of blood-brain distribution: The influence of plasma and brain tissue binding

Journal of Pharmaceutical Sciences

Volumn 100, Issue 6, 2011, Pages 2147-2160

  Lanevskij, Kiril ^a,b   Dapkunas, Justas ^a,b   Juska, Liutauras ^a,b   Japertas, Pranas ^a   Didziapetris, Remigijus ^a  

^a ACD/Labs Inc   (Lithuania)

^b VILNIUS UNIVERSITY   (Lithuania)

Author keywords

Blood brain barrier; CNS; Computational ADME; Drug transport; In silico modeling; Nonlinear regression; Passive diffusion; Plasma protein binding; QSAR; Tissue binding

Indexed keywords

ALFENTANIL; AMPRENAVIR; CETIRIZINE; CIMETIDINE; DESLORATADINE; DEXAMETHASONE; DIGOXIN; DIPHENHYDRAMINE; DOXORUBICIN; ELETRIPTAN; FENTANYL; FEXOFENADINE; HYDROXYZINE; INDINAVIR; IVERMECTIN; LOPERAMIDE; LORATADINE; METHADONE; MIDAZOLAM; MORPHINE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NARATRIPTAN; NELFINAVIR; PACLITAXEL; PETHIDINE; QUINIDINE; RANITIDINE; RITONAVIR; RIZATRIPTAN; SAQUINAVIR; UNINDEXED DRUG; VOLINANSERIN;

ARTICLE; BINDING AFFINITY; BRAIN TISSUE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DIFFUSION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG TRANSPORT; NONHUMAN; PARAMETER; PKA; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAT; STEADY STATE; STEADY STATE BLOOD TO BRAIN DISTRIBUTION RATIO; VALIDATION PROCESS;

EID: 79954609232     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22442     Document Type: Article

References (62)

1. Abbott N. 2004. Prediction of blood-brain barrier permeation in drug discovery from in vivo, in vitro and in silico models. Drug Discov Today Technol 1:407-416.
2. Goodwin J, Clark D. 2005. In silico predictions of blood-brain barrier penetration: Considerations to "keep in mind". J Pharmacol Exp Ther 315:477-483.
3. Mensch J, Oyarzabal J, Mackie C, Augustijns P. 2009. In vivo, in vitro and in silico methods for small molecule transfer across the BBB. J Pharm Sci 98:4429-4468.
4. Pangalos MN, Schechter LE, Hurko O. 2007. Drug development for CNS disorders: Strategies for balancing risk and reducing attrition. Nat Rev Drug Discov 6:521-532.
5. Di L, Kerns EH, Bezar IF, Petusky SL, Huang Y. 2009. Comparison of blood-brain barrier permeability assays: In situ brain perfusion, MDR1-MDCKII and PAMPA-BBB. J Pharm Sci 98:1980-1991.
6. Clark DE. 2003. In silico prediction of blood-brain barrier permeation. Drug Discov Today 8:927-933.
7. Lobell M, Molnár L, Keserü GM. 2003. Recent advances in the prediction of blood-brain partitioning from molecular structure. J Pharm Sci 92:360-370.
8. Fan Y, Unwalla R, Denny RA, Di L, Kerns EH, Diller DJ, Humblet C. 2010. Insights for predicting blood-brain barrier penetration of CNS targeted molecules using QSPR approaches. J Chem Inf Model 50:1123-1133.
9. Fu X, Wang G, Shan H, Liang W, Gao J. 2008. Predicting blood-brain barrier penetration from molecular weight and number of polar atoms. Eur J Pharm Biopharm 70:462-466.
10. Vilar S, Chakrabarti M, Costanzi S. 2010. Prediction of passive blood-brain partitioning: Straightforward and effective classification models based on in silico derived physicochemical descriptors. J Mol Graph Model 28:899-903.
11. Subramanian G, Kitchen DB. 2003. Computational models to predict blood-brain barrier permeation and CNS activity. J Comput Aided Mol Des 17:643-664.
12. Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, Cianfrogna J, Cox LM, Gibbs JP, Gibbs MA, Hatch H, Hop CECA, Kasman IN, Laperle J, Liu J, Liu X, Logman M, Maclin D, Nedza FM, Nelson F, Olson E, Rahematpura S, Raunig D, Rogers S, Schmidt K, Spracklin DK, Szewc M, Troutman M, Tseng E, Tu M, Van Deusen JW, Venkatakrishnan K, Walens G, Wang EQ, Wong D, Yasgar AS, Zhang C. 2005. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: Evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 33:165-174.
13. Lanevskij K, Japertas P, Didziapetris R, Petrauskas A. 2009. Ionization-specific prediction of blood-brain permeability. J Pharm Sci 98:122-134.
14. Abraham MH, Ibrahim A, Zhao Y, Acree WE. 2006. A database for partition of volatile organic compounds and drugs from blood/plasma/serum to brain, and an LFER analysis of the data. J Pharm Sci 95:2091-2100.
15. Zhang L, Zhu H, Oprea TI, Golbraikh A, Tropsha A. 2008. QSAR modeling of the blood-brain barrier permeability for diverse organic compounds. Pharm Res 25:1902-1914.
16. Norinder U, Haeberlein M. 2002. Computational approaches to the prediction of the blood-brain distribution. Adv Drug Deliv Rev 54:291-313.
17. Mehdipour AR, Hamidi M. 2009. Brain drug targeting: A computational approach for overcoming blood-brain barrier. Drug Discov Today 14:1030-1036.
18. Chen Y, Zhu Q, Pan J, Yang Y, Wu X. 2009. A prediction model for blood-brain barrier permeation and analysis on its parameter biologically. Comput Methods Programs Biomed 95:280-287.
19. Kalvass JC, Maurer TS, Pollack GM. 2007. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: Comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios. Drug Metab Dispos 35:660-666.
20. Hammarlund-Udenaes M, Fridén M, Syvänen S, Gupta A. 2008. On the rate and extent of drug delivery to the brain. Pharm Res 25:1737-1750.
21. Jeffrey P, Summerfield SG. 2007. Challenges for blood-brain barrier (BBB) screening. Xenobiotica 37:1135-1151.
22. Jeffrey P, Summerfield S. 2010. Assessment of the blood-brain barrier in CNS drug discovery. Neurobiol Dis 37:33-37.
23. Reichel A. 2009. Addressing central nervous system (CNS) penetration in drug discovery: Basics and implications of the evolving new concept. Chem Biodivers 6:2030-2049.
24. Wan H, Rehngren M, Giordanetto F, Bergström F, Tunek A. 2007. High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery. J Med Chem 50:4606-4615.
25. Wan H, Ahman M, Holmén AG. 2009. Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs. J Med Chem 52:1693-1700.
26. Rodgers T, Rowland M. 2007. Mechanistic approaches to volume of distribution predictions: Understanding the processes. Pharm Res 24:918-933.
27. Rodgers T, Leahy D, Rowland M. 2005. Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 94:1259-1276.
28. Rodgers T, Rowland M. 2006. Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95:1238-1257.
29. Lanevskij K, Japertas P, Didziapetris R, Petrauskas A. 2009. Ionization-specific QSAR models of blood-brain penetration of drugs. Chem Biodivers 6:2050-2054.
30. Kortagere S, Chekmarev D, Welsh WJ, Ekins S. 2008. New predictive models for blood-brain barrier permeability of drug-like molecules. Pharm Res 25:1836-1845.
31. Jeffrey P, Summerfield SG. 2007. Challenges for blood-brain barrier (BBB) screening. Xenobiotica 37:1135-1151.
32. Maurer TS, Debartolo DB, Tess DA, Scott DO. 2005. Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 33:175-181.
33. ACD/ADME Suite is available from ACD/Labs, Inc., Toronto, Ontario, Canada. Available at: Accessed September 13, 2010.
34. Kratochwil NA, Huber W, Müller F, Kansy M, Gerber PR. 2002. Predicting plasma protein binding of drugs: A new approach. Biochem Pharmacol 64:1355-1374.
35. Kubinyi H. 1977. Quantitative structure-activity relationships. 7. The bilinear model, a new model for nonlinear dependence of biological activity on hydrophobic character. J Med Chem 20:625-629.
36. Lanevskij K, Japertas P, Didziapetris R, Petrauskas A. 2010. Prediction of blood-brain barrier penetration by drugs. In Drug delivery to the central nervous system; Jain KK, Ed. 1st ed. New York: Humana Press, pp 63-83.
37. Tamai I, Tsuji A. 2000. Transporter-mediated permeation of drugs across the blood-brain barrier. J Pharm Sci 89:1371-1388.
38. Summerfield SG, Lucas AJ, Porter RA, Jeffrey P, Gunn RN, Read KR, Stevens AJ, Metcalf AC, Osuna MC, Kilford PJ, Passchier J, Ruffo AD. 2008. Toward an improved prediction of human in vivo brain penetration. Xenobiotica 38:1518-1535.
39. Poulin P, Theil FP. 2000. A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci 89:16-35.
40. Japertas P, Didziapetris R, Petrauskas A. 2002. Fragmental methods in the design of new compounds. Applications of the advanced algorithm builder. Quant Struct-Act Relat 21:23-37.
41. Kosa T, Maruyama T, Otagiri M. 1997. Species differences of serum albumins: I. Drug binding sites. Pharm Res 14:1607-1612.
42. R: A language and environment for statistical computing is available from R Foundation for Statistical Computing, Vienna, Austria. Available at: Accessed July 15, 2010.
43. Avdeef A. 2003. Absoption and drug development. 1st ed.New York: Wiley-Interscience.
44. Reynolds DP, Lanevskij K, Japertas P, Didziapetris R, Petrauskas A. 2009. Ionization-specific analysis of human intestinal absorption. J Pharm Sci 98:4039-4054.
45. Schmidt S, Gonzalez D, Derendorf H. 2010. Significance of protein binding in pharmacokinetics and pharmacodynamics. J Pharm Sci 99:1107-1122.
46. van de Waterbeemd H. 2005. Which in vitro screens guide the prediction of oral absorption and volume of distribution? Basic Clin Pharmacol Toxicol 96:162-166.
47. Abraham MH, Acree WE, Leo AJ, Hoekman D, Cavanaugh JE. 2010. Water-solvent partition coefficients and Delta Log P values as predictors for blood-brain distribution; application of the Akaike information criterion. J Pharm Sci 99:2492-2501.
48. Van Damme S, Langenaeker W, Bultinck P. 2008. Prediction of blood-brain partitioning: A model based on ab initio calculated quantum chemical descriptors. J Mol Graph Model 26:1223-1236.
49. Yang Z, Zadjura L, D'Arienzo C, Marino A, Santone K, Klunk L, Greene D, Lin P, Colonno R, Wang T, Meanwell N, Hansel S. 2005. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics. Biopharm Drug Dispos 26:387-402.
50. Drion N, Risede P, Cholet N, Chanez C, Scherrmann JM. 1997. Role of P-170 glycoprotein in colchicine brain uptake. J Neurosci Res 49:80-88.
51. Young RC, Mitchell RC, Brown TH, Ganellin CR, Griffiths R, Jones M, Rana KK, Saunders D, Smith IR, Sore NE. 1988. Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists. J Med Chem 31:656-671.
52. Yazdanian M. 1999. Blood-brain barrier properties of human immunodeficiency virus antiretrovirals. J Pharm Sci 88:950-954.
53. Wang Y, Aun R, Tse F. 1998. Brain uptake of dihydroergotamine after intravenous and nasal administration in the rat. Biopharm Drug Dispos 19:571-575.
54. Pereira de Oliveira M, Olivier J, Pariat C, Roche D, Greiner J, Vierling P, Couet W. 2005. Investigation of oral bioavailability and brain distribution of the Ind(8)-Val conjugate of indinavir in rodents. J Pharm Pharmacol 57:453-458.
55. Tsai T. 2002. Determination of naringin in rat blood, brain, liver, and bile using microdialysis and its interaction with cyclosporin a, a p-glycoprotein modulator. J Agric Food Chem 50:6669-6674.
56. de Lange EC, Marchand S, van den Berg D, van der Sandt IC, de Boer AG, Delon A, Bouquet S, Couet W. 2000. In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin. Eur J Pharm Sci 12:85-93.
57. El Mohsen MA, Marks J, Kuhnle G, Moore K, Debnam E, Kaila Srai S, Rice-Evans C, Spencer JPE. 2006. Absorption, tissue distribution and excretion of pelargonidin and its metabolites following oral administration to rats. Br J Nutr 95:51-58.
58. Vink SR, Schellens JHM, van Blitterswijk WJ, Verheij M. 2005. Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. Invest New Drugs 23:279-286.
59. Cohen BM, Tsuneizumi T, Baldessarini RJ, Campbell A, Babb SM. 1992. Differences between antipsychotic drugs in persistence of brain levels and behavioral effects. Psychopharmacology (Berl) 108:338-344.
60. Grauer MT, Uhr M. 2004. P-glycoprotein reduces the ability of amitriptyline metabolites to cross the blood brain barrier in mice after a 10-day administration of amitriptyline. J Psychopharmacol 18:66-74.
61. Geerts H, Guillaumat P, Grantham C, Bode W, Anciaux K, Sachak S. 2005. Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits. Brain Res 1033:186-193.
62. Mahar Doan KM, Wring SA, Shampine LJ, Jordan KH, Bishop JP, Kratz J, Yang E, Serabjit-Singh CJ, Adkison KK, Polli JW. 2004. Steady-state brain concentrations of antihistamines in rats: Interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding. Pharmacology 72:92-98.